N‐monodesmethyldiltiazem is the predominant metabolite of diltiazem in the plasma of young and elderly hypertensives.

SC Montamat, DR Abernethy

Research output: Contribution to journalArticlepeer-review

43 Scopus citations


1 Twelve young (ages 30‐39 years) and twelve elderly (ages 65‐83 years) hypertensives were administered diltiazem twice daily for 2 weeks at doses up to 240 mg day‐1. 2 Plasma was analysed for diltiazem, N‐ monodesmethyldiltiazem, and desacetyldiltiazem concentrations after a single 10 min intravenous infusion of 21.8 mg diltiazem HCl on day 1 and after the morning oral dose of 120 mg diltiazem base on day 14. 3 N‐ monodesmethyldiltiazem accumulated to higher plasma concentrations than desacetyldiltiazem at steady state on day 14 in both age groups. 4 Prolongation of plasma diltiazem half‐life occurred after 2 weeks of oral diltiazem therapy in both age groups. 5 There were no significant differences between the young and elderly with regard to half‐life, area under the curve, and the peak and trough plasma concentrations of diltiazem, N‐monodesmethyldiltiazem, and desacetyldiltiazem; systemic clearance and volume of distribution of diltiazem were also similar in both groups. 1987 The British Pharmacological Society

Original languageEnglish (US)
Pages (from-to)185-189
Number of pages5
JournalBritish Journal of Clinical Pharmacology
Issue number2
StatePublished - Aug 1987
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'N‐monodesmethyldiltiazem is the predominant metabolite of diltiazem in the plasma of young and elderly hypertensives.'. Together they form a unique fingerprint.

Cite this